Published in Gene Therapy Weekly, September 8th, 2005
For the quarter ended June 30, 2005, Sirna reported a net loss applicable to common stock of $5.9 million, or $0.14 per share, compared to a net loss applicable to common stock of $6.3 million, or $0.18 per share, for the same period in 2004.
Sirna ended the second quarter with $18.7 million in cash and marketable securities. Subsequently, on July 5, the company entered into definitive agreements for the sale of common stock and warrants in a private placement for aggregate gross proceeds of $28 million. Revenues for the second quarter of 2005 were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.